ZEB2

Across TCGA pan-cancer cohorts, ZEB2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ZEB2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZEB2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZEB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, OV, and HNSC are the cancer types where ZEB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.951	0.419	.001	34	view →
OV	OS	Median	All	0.261	0.842	.012	18	view →
HNSC	OS	Median	All	0.169	0.710	.008	18	view →
LIHC	DFS	Median	All	0.060	0.531	<.001	11	view →
STAD	OS	Median	III,IV	0.113	0.642	<.001	9	view →
PRAD	DFS	Median	All	0.609	0.936	.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LUSC	DFS	Median	III,IV	0.197	0.646	.005	6	view →
BLCA	OS	Median	IV	0.509	0.284	.009	2	view →
SKCM	DFS	Median	III,IV	0.802	0.236	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ZEB2–UCEC (DFS)

Open the UCEC breakdown →